Fig. 3From: Short-term results of early switch from Ranibizumab to Aflibercept in poor or non responder age related macular degeneration in clinical practiceCentral macular thickness (CMT) monthly variation, measured in μm, after the third dose of ranibizumab (ARBZ), after the first dose of Aflibercept (AFL1), after the second dose of aflibercept (AFL2), after the third dose of aflibercept (AFL3); NR non-responder, PR poor responderBack to article page